Litigation

Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited et al.

settled

1:22-cv-01277-GBW

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Filed
2022-09-28
Terminated
2025-06-10

Patents at issue (6)

9314464
9850229
10005761
9562016
9598376
9980944

Summary

Hatch-Waxman ANDA litigation brought by Array BioPharma against Alembic over generic binimetinib 15 mg tablets (ANDA No. 217678). The case was terminated by stipulated dismissal after a confidential settlement and license agreement, expressly not an adjudication on the merits, with no finding of infringement, invalidity, or unenforceability. A May 28, 2024 stipulated order addressed certain claims but did not become a final, appealable judgment.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).